Emmes Group advances data security as ISMS certified ISO compliant
Gold-standard accreditation underscores Emmes Group's commitment to secure and data-rich trials for biotech and pharma partners
The new commendation, given by International Organization for Standardization (ISO), highlights Emmes Group's ongoing commitment to providing secure, innovative, and data-driven solutions to its biotech and pharmaceutical partners. As the clinical trial industry evolves with the integration of artificial intelligence and advanced analytics, robust data security is increasingly vital to protecting trial integrity and both sensitive patient and customer data.
Commenting on the accreditation,
ISO/IEC 27001:2022 provides a framework for establishing, implementing, maintaining, and continually improving an organization's ISMS. The 2022 revision introduces updated security controls designed to address modern challenges [Annex A], categorized into four domains. These controls address aspects of information security, such as access control, cryptography, physical security, and incident management – including cloud security, supply chain vulnerabilities, and emerging technologies such as AI.
By implementing these advanced controls, Emmes Group safeguards sensitive clinical trial information from breaches or unauthorized access, while aligning with global regulations, such as HIPAA and GDPR.
Notes to editors
About Emmes Group:
Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (https://www.newmountaincapital.com). The company is transforming the future of clinical research, bringing the promise of new medical discovery closer within reach for patients. Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Today, the company is transforming the future of clinical research, by creating the industry's first specialty, tech and AI based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence. Learn more at www.theemmesgroup.com.
About Emmes CRO:
Emmes CRO, founded more than 45-years ago, is a global, full-service Clinical Research Organization dedicated to the advancement of public health and biopharmaceutical innovation. Emmes CRO has supported more than 2,000 clinical trials across numerous agencies and institutes of the
View original content to download multimedia:https://www.prnewswire.com/news-releases/emmes-group-advances-data-security-as-isms-certified-iso-compliant-302374093.html
SOURCE Emmes Group
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
- CGTN: Why the world is asking: What makes the CPC work?
- R|Elan™ Circular Design Challenge Celebrates Its 8th Season with a Landmark Global Edition Under the India–France Year of Innovation 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share